argenx SE (ARGX.BR)
EUR 610.0
(1.77%)
EUR 610.0
(1.77%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 281.12 Million EUR | 23.11% |
| 2022 | 228.35 Million USD | 109.35% |
| 2021 | 109.07 Million USD | 331.93% |
| 2020 | 25.25 Million EUR | 2229.23% |
| 2019 | 1.08 Million EUR | 101054018719188.89% |
| 2018 | - EUR | -100.0% |
| 2017 | 2.00 EUR | 200324867.16% |
| 2016 | - EUR | -100.0% |
| 2015 | 1.00 EUR | -100.0% |
| 2014 | 111.87 Thousand EUR | -23.57% |
| 2013 | 146.37 Thousand EUR | 30.21% |
| 2012 | 112.41 Thousand EUR | 70.07% |
| 2011 | 66.1 Thousand EUR | 10424550.74% |
| 2010 | 0.63 EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | 326.46 Million EUR | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | 201.11 Million USD | 0.0% |
| 2023 FY | 281.12 Million EUR | 23.11% |
| 2023 Q4 | 310.55 Million USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2022 FY | 228.35 Million USD | 109.35% |
| 2022 Q2 | 135.71 Million USD | 0.0% |
| 2022 Q4 | 228.35 Million USD | 0.0% |
| 2021 Q4 | 109.07 Million USD | 0.0% |
| 2021 FY | 109.07 Million USD | 331.93% |
| 2021 Q2 | 59.21 Million USD | 0.0% |
| 2020 Q4 | 25.25 Million EUR | 0.0% |
| 2020 Q2 | 5.59 Million EUR | 0.0% |
| 2020 FY | 25.25 Million EUR | 2229.23% |
| 2019 FY | 1.08 Million EUR | 101054018719188.89% |
| 2019 Q2 | 1.00 EUR | 0.0% |
| 2019 Q4 | -1.08 Million EUR | 0.0% |
| 2018 Q2 | 1.00 EUR | 0.0% |
| 2018 FY | - EUR | -100.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2017 FY | 2.00 EUR | 200324867.16% |
| 2017 Q4 | 2.00 EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 FY | - EUR | -100.0% |
| 2015 FY | 1.00 EUR | -100.0% |
| 2015 Q2 | 492.38 Thousand EUR | 0.0% |
| 2015 Q4 | 1.00 EUR | 0.0% |
| 2014 Q1 | 1.00 EUR | -100.0% |
| 2014 Q4 | 111.87 Thousand EUR | 0.0% |
| 2014 Q2 | 1.00 EUR | 0.0% |
| 2014 FY | 111.87 Thousand EUR | -23.57% |
| 2013 Q4 | 146.37 Thousand EUR | 0.0% |
| 2013 FY | 146.37 Thousand EUR | 30.21% |
| 2012 FY | 112.41 Thousand EUR | 70.07% |
| 2011 FY | 66.1 Thousand EUR | 10424550.74% |
| 2010 FY | 0.63 EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -127108.04% |
| ABIVAX Société Anonyme | 1.00 EUR | -28112976800.0% |
| Adocia SA | 272 Thousand EUR | -103256.533% |
| Aelis Farma SA | 53 Thousand EUR | -530333.526% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | -16047.603% |
| genOway Société anonyme | 982.75 Thousand EUR | -28506.409% |
| IntegraGen SA | 311.44 Thousand EUR | -90165.106% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -170672.903% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 25457.71% |
| Plant Advanced Technologies SA | 1.22 Million EUR | -22857.559% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 235994.617% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -308833.812% |
| Valbiotis SA | 1 Million EUR | -27873.139% |
| TheraVet SA | 123.34 Thousand EUR | -227827.039% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -28112976800.0% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | -22211.886% |
| DBV Technologies S.A. | 1.00 USD | -28112976800.0% |
| Galapagos NV | 73.97 Million EUR | -280.018% |
| Genfit S.A. | 4000.00 EUR | -7028144.225% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -28112976800.0% |
| Innate Pharma S.A. | 1.00 EUR | -28112976800.0% |
| Inventiva S.A. | 417 Thousand EUR | -67317.211% |
| MaaT Pharma SA | 190 Thousand EUR | -147863.036% |
| MedinCell S.A. | -6.71 Million EUR | 4287.217% |
| Nanobiotix S.A. | 200 Thousand EUR | -140464.885% |
| Onward Medical N.V. | 936 Thousand EUR | -29935.232% |
| Oryzon Genomics S.A. | 6029.00 EUR | -4662858.517% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -219532.632% |
| Pharming Group N.V. | 51.38 Million EUR | -447.128% |
| Poxel S.A. | 2.95 Million EUR | -9410.479% |
| GenSight Biologics S.A. | 1.00 EUR | -28112976800.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 72.732% |
| Valneva SE | 44.46 Million EUR | -532.235% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -28112976800.0% |